Forester Capital Management LTD maintained its position in GlaxoSmithKline PLC (NYSE:GSK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,630 shares of the pharmaceutical company’s stock at the end of the first quarter. Forester Capital Management LTD’s holdings in GlaxoSmithKline PLC were worth $195,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. raised its position in GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares in the last quarter. Heritage Trust Co bought a new position in GlaxoSmithKline PLC during the first quarter valued at approximately $123,000. Advisory Services Network LLC bought a new position in GlaxoSmithKline PLC during the first quarter valued at approximately $137,000. Menora Mivtachim Holdings LTD. bought a new position in GlaxoSmithKline PLC during the fourth quarter valued at approximately $138,000. Finally, Advisors Preferred LLC bought a new position in GlaxoSmithKline PLC during the first quarter valued at approximately $140,000. Institutional investors own 8.97% of the company’s stock.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC (NYSE GSK) traded up 0.90% during mid-day trading on Friday, hitting $43.82. 1,920,459 shares of the stock traded hands. The stock has a 50-day moving average price of $42.98 and a 200-day moving average price of $40.87. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $45.58. The stock has a market cap of $107.05 billion, a P/E ratio of 50.14 and a beta of 1.04.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share for the quarter, meeting the consensus estimate of $0.62. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. The business had revenue of $9.23 billion during the quarter, compared to analysts’ expectations of $9.09 billion. On average, equities analysts forecast that GlaxoSmithKline PLC will post $2.82 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 13th. Investors of record on Friday, May 12th will be given a dividend of $0.483 per share. The ex-dividend date is Wednesday, May 10th. This represents a $1.93 dividend on an annualized basis and a dividend yield of 4.41%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 232.53%.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Stake Held by Forester Capital Management LTD” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-stake-held-by-forester-capital-management-ltd/1372273.html.

Several research analysts recently commented on GSK shares. BNP Paribas dropped their price target on GlaxoSmithKline PLC to $37.00 in a research report on Thursday, April 6th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Liberum Capital started coverage on GlaxoSmithKline PLC in a research report on Thursday, March 9th. They issued a “buy” rating for the company. Jefferies Group LLC reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Sunday, February 19th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $45.25.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.